Privo Technologies, Inc. To Attend Biotech Showcase January 17 to January 19, 2022Peter Goldberg
Peabody, MA– Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy on patients”, announced today that the Company will be attending the virtual Biotech Showcase from January 17 to January 19, 2022. Members of Privo’s management team will be available for 1×1 meetings with interested parties. Those registered for the event can request a meeting with Privo through the partneringOne portal.
About Privo Technologies, Inc.
Privo Technologies, Inc. (Privo) is a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal mucosal cancers. Privo is headquartered in Peabody, Massachusetts. Privo’s initial focus is on oral cavity cancers for their two lead assets PRV111 and PRV211. PRV111 is a derivative of the PRV platform, a novel nanotechnology-based system that is capable of improving the efficacy of potent anticancer drugs and significantly improving their safety through locoregional delivery. This approach eliminates needles, avoids stomach acids, significantly reduces toxic side effects of drugs, and allows for higher dosing where the drugs can be most effective – all of which have the potential to improve patient outcomes and compliance. This platform has broad potential applications for use in other mucosal cancers, including anal, colorectal, genitourinary, nasal, and skin cancers. Another derivative, PRV211, is a sterilized, rapid release chemotherapy patch that can be applied intraoperatively post-tumor resection to potentially reduce the risk of cancer recurrence.
For additional information on Privo Technologies, Inc. please visit www.privotechnologies.com.